| HOME >> BIOLOGY >> TECHNOLOGY |
AMSTERDAM, March 20 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today announced that AMT's Supervisory Board has decided to propose Alexander Ribbink to be appointed to the Supervisory Board at its Annual General Meeting of shareholders on April 16, 2008. Mr. Ribbink is Chief Operating Officer of TomTom (Euronext Amsterdam: TOM2), and has been instrumental in building TomTom into the world's largest portable navigation solutions provider.
Mr. Ribbink, who joined TomTom in 2003, spent 11 years with Unilever, specializing in consumer marketing and general management, becoming vice-president for brand development for one of the company's largest Dutch food subsidiaries. He later managed a key European business unit for Mars, Inc.
Further to a plan of rotation that aims to build a fully independent Supervisory Board in the course of 2008, AMT expects to propose several other independent candidates to replace current non-independent members. Earlier this year, AMT announced the nomination of Mr. Philippe van Holle, Head of Celgene Europe (NASDAQ: CELG), to its Supervisory Board.
AMT's AGM is scheduled for April 16, 10:30 a.m., and will take place at the Rosarium, Amsterdam, The Netherlands.
About Amsterdam Molecular Therapeutics
AMT has a unique gene therapy platform that to date appears to
circumvent many if not all of the obstacles that have prevented gene
therapy from becoming a mainstay of clinical medicine. Using
adeno-associated viral (AAV) vectors as the delivery vehicle of choice for
therapeutic genes, the company has been able to design and validate what is
probably the first stable and scalable AAV production platform. As s
'/>"/>
| SOURCE Amsterdam Molecular Therapeutics B.V Copyright©2008 PR Newswire. All rights reserved |